Search Result

Results for "

Fibrin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Autophagy (2) Bacterial (3) Cytochrome P450 (1) Dengue Virus (1) Endogenous Metabolite (1) Factor Xa (3) Factor XI (2) Flavivirus (1) Fluorescent Dye (2) Heme Oxygenase (HO) (1) Integrin (5) Interleukin Related (1) Liposome (3) NF-κB (1) PAI-1 (5) Parasite (1) Reactive Oxygen Species (1) Ser/Thr Protease (1) TGF-beta/Smad (2) Thrombin (11)
By Research Areas:	Cancer (10) Cardiovascular Disease (23) Infection (1) Inflammation/Immunology (6) Metabolic Disease (4) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0665

*Fibrin*	Integrin	Cardiovascular Disease Cancer
Fibrin, isolated from bovine blood, is an insoluble protein produced in response to bleeding. Fibrin is the major component of the blood clot and is used for coagulation .

HY-106275

FX-06 Fibrin-derived peptide Bβ15-42	Flavivirus Dengue Virus	Cardiovascular Disease
FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS) .

HY-125864

Fibrinogen (Bovine)	Interleukin Related NF-κB	Inflammation/Immunology
Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .

HY-P0074

GPRP 1 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Integrin	Cardiovascular Disease
GPRP (Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .

HY-P0074A

GPRP acetate 1 Publications Verification Gly-Pro-Arg-Pro acetate; Pefa 6003 acetate	Integrin	Cardiovascular Disease
GPRP acetate (Gly-Pro-Arg-Pro acetate) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .

HY-P2373

Nattokinase, Natto fermentation 1 Publications Verification	PAI-1	Cardiovascular Disease
Nattokinase, Natto fermentation is a potent fibrinolytic enzyme. Nattokinase can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Nattokinase can be used for the research of cardiovascular diseases .

HY-W040030

Hematin	Cytochrome P450	Metabolic Disease Cancer
Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins . Hematin can be used for the research of acute porphyrias and cancer .

HY-P10293

NQEQVSP	Thrombin Others	Others
NQEQVSP, a fibrin-binding protein-derived peptide (FBP), is a factor XIIIa substrate. NQEQVSP can be recognized by factor XIII and is enzymatically conjugated into fibrin during polymerization .

HY-P4721

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated)	Thrombin	Cardiovascular Disease
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a K_D < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .

HY-E70230

Staphylokinase, staphylococcus aureus SAK	Ser/Thr Protease	Cardiovascular Disease
Staphylokinase, staphylococcus aureus (SAK) is a fibrin-specific plasminogen activator. Staphylokinase is an efficient, fibrin-selective thrombolytic agent .

HY-122311

Orniplabin SMTP-7	Reactive Oxygen Species	Neurological Disease Inflammation/Immunology
Orniplabin (SMTP-7) is a low-molecular-weight compound that enhances plasminogen–fibrin binding, urokinase-catalyzed activation of plasminogen, and urokinase and plasminogen-mediated fibrin degradation. Orniplabin shows potential thrombolytic and anti-inflammatory effects. Orniplabin inhibits ROS .

HY-107911

Protamine sulfate 2 Publications Verification	Thrombin	Metabolic Disease
Protamine sulfate, polycationic peptide and a antiheparin agent, could neutralize the anticoagulant action of heparin and enhances lipid-mediated gene transfer .

HY-D1480

Crystal Ponceau 6R	Fluorescent Dye	Others
Crystal Ponceau 6R is a red azo dye. Crystal Ponceau 6R used in histology, for staining fibrin with the martius, scarlet and blue (MSB) Trichrome stain .

HY-114150

D-Val-Leu-Arg-pNA	PAI-1	Others
D-Val-Leu-Arg-pNA is a glandular kininoreleasing enzyme substrate that also acts as a substrate for tissue-type plasminogen activator (t-PA) with no apparent affinity for fibrin .

HY-N1400

(20R)-Ginsenoside Rh1	Others	Cancer
(20R)-Ginsenoside Rh1, the R isomer of Ginsenoside Rh1 isolated from Panax Ginseng, inhibits the thrombin-induced conversion of fibrinogen to fibrin .

HY-P3160

Fibronectin 4 Publications Verification	Integrin	Cardiovascular Disease Inflammation/Immunology
Fibronectin, a glycoprotein present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans .

HY-76971

Dechloro Rivaroxaban	Factor Xa	Cardiovascular Disease
Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a K_i of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC₅₀s of 2.1 nM and 92 nM, respectively .

HY-P991213

Nonacog gamma	Factor XI	Cardiovascular Disease
Nonacog gamma is a coagulation factor IX (FIX) supplement. Nonacog gamma activates coagulation factor X (FX), promotes the generation of thrombin, and then converts fibrinogen into fibrin, forming a stable blood clot to exert hemostatic activity. Nonacog gamma is promising for research of hemophilia B .

HY-107966

Heparin calcium (MW 15000-19000) Nadroparin calcium (MW 15000-19000)	Thrombin Factor Xa Autophagy Bacterial	Cardiovascular Disease Cancer
Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-107966A

Heparin calcium (MW 3600-5000) Nadroparin calcium (MW 3600-5000)	Thrombin Factor Xa Autophagy Bacterial	Cardiovascular Disease Cancer
Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-12586

AZD6564	Thrombin	Others
AZD6564 is an orally active inhibitor for fibrinolysis through disruption of plasma kinase-fibrin interaction. AZD6564 dissolves human plasma clot with an IC₅₀ of 0.44 μM. AZD6564 ameliorates hemorrhage in rats with EC₅₀ of 1.62 μM, and exhibits good pharmacokinetic characteristics in rats .

HY-172497

DSPE-PEG2000-CREKA	Liposome	Cancer
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-CREKA	Liposome	Cancer
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-CREKA	Liposome	Cancer
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-122542

PPACK	Thrombin PAI-1	Cardiovascular Disease
PPACK is potent, selective and irreversible thrombin inhibitor. PPACK can be used an alternative anticoagulant to lithium heparin (LiHep) for blood gas and whole-blood electrolyte analyses. PPACK is also a plasminogen activator (rt-PA) inhibitor. PPACK can inhibit the binding of rt-PA to plasma protease inhibitors .

HY-123120

SA-152	Thrombin	Others
SA-152 is an organophosphorus inhibitor. SA-152 modulates the fibrinogen coagulation and TAME esterase activity of bovine α-thrombin .

HY-122542A

PPACK dihydrochloride Pebac; D-Phenylalanyl-prolyl-arginyl Chloromethyl Ketone; D-Phe-Pro-Arg-CH2Cl	Thrombin PAI-1	Cardiovascular Disease
PPACK dihydrochloride is potent, selective and irreversible thrombin inhibitor. PPACK dihydrochloride can be used an alternative anticoagulant to lithium heparin (LiHep) for blood gas and whole-blood electrolyte analyses. PPACK dihydrochloride is also a plasminogen activator (rt-PA) inhibitor. PPACK dihydrochloride can inhibit the binding of rt-PA to plasma protease inhibitors .

HY-P991211

Bemiltenase alfa	Factor XI	Cardiovascular Disease
Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia .

HY-128394R

L-Gulose (Standard)	Endogenous Metabolite	Metabolic Disease
(20R)-Ginsenoside Rh1 (Standard) is the analytical standard of (20R)-Ginsenoside Rh1. This product is intended for research and analytical applications. (20R)-Ginsenoside Rh1, the R isomer of Ginsenoside Rh1 isolated from Panax Ginseng, inhibits the thrombin-induced conversion of fibrinogen to fibrin .

HY-N1400R

(20R)-Ginsenoside Rh1 (Standard)	Others	Cancer
(20R)-Ginsenoside Rh1 (Standard) is the analytical standard of (20R)-Ginsenoside Rh1. This product is intended for research and analytical applications. (20R)-Ginsenoside Rh1, the R isomer of Ginsenoside Rh1 isolated from Panax Ginseng, inhibits the thrombin-induced conversion of fibrinogen to fibrin .

HY-124499

RUC-1	Integrin	Cardiovascular Disease
RUC-1 (Compound 1) is an inhibitor for αIIbβ3 integrin. RUC-1 inhibits fibrin deposition and platelet aggregation in hybrid hαIIb/mβ3 receptors expressing mice. RUC-1 exhibits antithrombotic effect in hαIIb/mβ3 receptor expressing mice .

HY-10275

Atecegatran AR-H067637	Thrombin	Cardiovascular Disease
Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a K_i of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC₅₀ ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders .

HY-P5356

H-D-Val-Leu-Lys-AFC Plasmin substrate	Fluorescent Dye	Others
H-D-Val-Leu-Lys-AFC (Plasmin substrate) is a biological active peptide. (This is a fluorescent plasmin substrate, Abs/Em=380/500 nm.Plasmin belongs to the family of serine proteases. It plays a key role in fibrinolysis by dissolving fibrin in blood clots. Besides fibrinolysis, plasmin is also involved in such physiological and pathological processes as wound healing, liver repair, and the maintenance of liver homeostasis.)

HY-122542B

PPACK TFA 1 Publications Verification	Thrombin PAI-1	Cardiovascular Disease
PPACK TFA is potent, selective and irreversible thrombin inhibitor. PPACK TFA can be used an alternative anticoagulant to lithium heparin (LiHep) for blood gas and whole-blood electrolyte analyses. PPACK TFA is also a plasminogen activator (rt-PA) inhibitor. PPACK TFA can inhibit the binding of rt-PA to plasma protease inhibitors .

HY-B1064

Clindamycin phosphate 4 Publications Verification Clindamycin 2-phosphate; U-28508	Bacterial Antibiotic Parasite	Infection Cancer
Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis .Clindamycin phosphate has no cytotoxicity. Combined with platelet rich fibrin (PRF), PRF-Clindamycin phosphate enhances antimicrobial properties .

HY-W854721

Mn(III) Protoporphyrin IX chloride Manganese(III) Protoporphyrin IX Chloride	Heme Oxygenase (HO)	Metabolic Disease
Mn(III) protoporphyrin IX chloride is a metalloporphyrin. It induces mRNA expression of the genes encoding δ-aminolevulinate synthase and heme oxygenase (HO), enzymes that catalyze the rate-limiting steps of heme biosynthesis and degradation, respectively, in chick embryo liver cells when used at a concentration of 10 μM. Mn(III) protoporphyrin IX chloride-containing nanobialys have been used in magnetic resonance imaging (MRI) of fibrin clots in vitro. It has also been used in the synthesis of Mn(III) protoporphyrin IX-6(7)-glycyl-glycyl-L-histidine methyl ester (MnGGH), a metalloporphyrin conjugate with microperoxidase activity.

HY-16268A

Kartogenin sodium Maximum Cited Publications 23 Publications Verification KGN sodium	TGF-beta/Smad	Inflammation/Immunology
Kartogenin (KGN) sodium is an inducer of chondrogenic tissue formation (EC₅₀: 100 nM). Kartogenin sodium induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin sodium also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin sodium is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin sodium promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .

HY-16268

Kartogenin Maximum Cited Publications 23 Publications Verification KGN	TGF-beta/Smad	Inflammation/Immunology
Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC₅₀: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .

Cat. No.	Product Name

HY-L136

Coagulation and Anti-coagulation Compound Library	1,184 compounds
Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation. Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process. MCE supplies a unique collection of 1,184 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Coagulation and Anti-coagulation Compound Library

1,184 compounds

Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation.

Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process.

MCE supplies a unique collection of 1,184 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Cat. No.	Product Name	Type

HY-125864

Fibrinogen (Bovine)	Native Proteins
Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .

Fibrinogen (Bovine)

Native Proteins

Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .

HY-107911

Protamine sulfate 2 Publications Verification	Native Proteins
Protamine sulfate, polycationic peptide and a antiheparin agent, could neutralize the anticoagulant action of heparin and enhances lipid-mediated gene transfer .

HY-P3160

Fibronectin 4 Publications Verification	Native Proteins
Fibronectin, a glycoprotein present in blood as well as in cells, is a biomarker of tissue injury. Fibronectin binds to membrane-spanning receptor proteins called integrins. Fibronectin also binds to other extracellular matrix proteins such as collagen, fibrin, and heparan sulfate proteoglycans .

HY-107966A

Heparin calcium (MW 3600-5000) Nadroparin calcium (MW 3600-5000)	Cell Assay Reagents
Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-107966

Heparin calcium (MW 15000-19000) Nadroparin calcium (MW 15000-19000)	Cell Assay Reagents
Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-172497

DSPE-PEG2000-CREKA	Drug Delivery
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-CREKA	Drug Delivery
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-CREKA	Drug Delivery
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-106275

FX-06 Fibrin-derived peptide Bβ15-42	Flavivirus Dengue Virus	Cardiovascular Disease
FX-06 (Fibrin-derived peptide Bβ15-42) is a fibrin Bbeta chain-derived peptide. FX-06 binds to VE-cadherin and inhibits leukocyte transmigration and initiates VE-cadherin-mediated signaling. FX-06 can be used in the research of ischemia/reperfusion injury, Dengue shock syndrome (DSS) .

HY-P1493A

Fibrinopeptide B, human TFA FPB,human TFA	Peptides	Inflammation/Immunology
Fibrinopeptide B, human TFA (FPB,human TFA), human is a 14-aa peptide, released from the amino-terminus of β-chains of fibrinogen by thrombin .

HY-P0074

GPRP 1 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Integrin	Cardiovascular Disease
GPRP (Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .

HY-P0074A

GPRP acetate 1 Publications Verification Gly-Pro-Arg-Pro acetate; Pefa 6003 acetate	Integrin	Cardiovascular Disease
GPRP acetate (Gly-Pro-Arg-Pro acetate) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa) .

HY-P3531

Fibrinogen γ-chain (397-411)	Peptides	Others
Fibrinogen γ-chain (397-411), a esidues 397-411 of the γ chain of fibrinogen, is a site recognizing the platelet receptor, which is distinct from the site(s) involved in polymerization of fibrin monomers .

HY-P2708

H-Gly-Pro-Arg-Pro-NH2	Peptides	Cardiovascular Disease
H-Gly-Pro-Arg-Pro-NH2 is a peptide that mimics the N-terminal Gly-Pro-Arg region in the a chain of fibrin protein. H-Gly-Pro-Arg-Pro-NH2 prevents fibrin polymerization .

HY-P10293

NQEQVSP	Thrombin Peptides	Others
NQEQVSP, a fibrin-binding protein-derived peptide (FBP), is a factor XIIIa substrate. NQEQVSP can be recognized by factor XIII and is enzymatically conjugated into fibrin during polymerization .

HY-P4721

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated)	Thrombin	Cardiovascular Disease
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a K_D < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .

HY-114150

D-Val-Leu-Arg-pNA	PAI-1	Others
D-Val-Leu-Arg-pNA is a glandular kininoreleasing enzyme substrate that also acts as a substrate for tissue-type plasminogen activator (t-PA) with no apparent affinity for fibrin .

HY-P4269

Glycylglycylcysteine	Peptides	Cardiovascular Disease
Glycylglycylcysteine is a Thrombin Activatable Fibrinolysis Inhibitor (TAFI) inhibitor with a K_i of 0.99 μM and a IC₅₀ of 9.4 μM in TAFI substrate assays. TAFI is a basic carboxypeptidase that functions as a fibrinolysis inhibitor through the cleavage of C-terminal lysine on partially degraded fibrin .

HY-122542

PPACK	Thrombin PAI-1	Cardiovascular Disease
PPACK is potent, selective and irreversible thrombin inhibitor. PPACK can be used an alternative anticoagulant to lithium heparin (LiHep) for blood gas and whole-blood electrolyte analyses. PPACK is also a plasminogen activator (rt-PA) inhibitor. PPACK can inhibit the binding of rt-PA to plasma protease inhibitors .

HY-P3082

SKF 106760	Peptides	Cardiovascular Disease
SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .

HY-P5356

H-D-Val-Leu-Lys-AFC Plasmin substrate	Fluorescent Dye	Others
H-D-Val-Leu-Lys-AFC (Plasmin substrate) is a biological active peptide. (This is a fluorescent plasmin substrate, Abs/Em=380/500 nm.Plasmin belongs to the family of serine proteases. It plays a key role in fibrinolysis by dissolving fibrin in blood clots. Besides fibrinolysis, plasmin is also involved in such physiological and pathological processes as wound healing, liver repair, and the maintenance of liver homeostasis.)

HY-P5121

γ-Fibrinogen 377-395	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation .

HY-P5121A

γ-Fibrinogen 377-395 TFA	Peptides	Cardiovascular Disease
γ-Fibrinogen377-395 TFA is a fibrinogen-derived inhibitory peptide, as well as fibrinogen epitope. γ-Fibrinogen377-395 TFA blocks microglia activation and inhibits fibrin-Mac-1 interactions in vitro, and suppresses experimental autoimmune encephalomyelitis (EAE) in mice in vivo. γ-Fibrinogen377-395 TFA can be used for research in multiple sclerosis (MS), and other neuroinflammatory diseases associated with blood-brain barrier disruption and microglia activation .

Cat. No.	Product Name	Target	Research Area

HY-P991213

Nonacog gamma	Factor XI	Cardiovascular Disease
Nonacog gamma is a coagulation factor IX (FIX) supplement. Nonacog gamma activates coagulation factor X (FX), promotes the generation of thrombin, and then converts fibrinogen into fibrin, forming a stable blood clot to exert hemostatic activity. Nonacog gamma is promising for research of hemophilia B .

HY-P991211

Bemiltenase alfa	Factor XI	Cardiovascular Disease
Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81886

	Factor XIIIa Antibody (YA1631) Coagulation factor XIIIa; F13A; F13a1; Fibrin stabilizing factor; A subunit; Fibrinoligase; TGase; Transglutaminase A chain	WB, IHC-P	Human
	Factor XIIIa Antibody (YA1631) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1631), targeting Factor XIIIa, with a predicted molecular weight of 83 kDa (observed band size: 83 kDa). Factor XIIIa Antibody (YA1631) can be used for WB, IHC-P experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks